Posted by Michael Wonder on 03 Jun 2025
MaaT Pharma submits marketing authorisation application to the EMA for Xervyteg (MaaT013) in acute graft versus host disease
2 June 2025 - The marketing authorisation application submitted to the EMA is based on data from the Pivotal ARES study, evaluating the safety and efficacy of Xervyteg in adult patients with acute graft versus host disease including gastro-intestinal involvement who received two prior lines of therapy and supported by data from the on-going Early Access Program.
MaaT Pharma today announced the submission of the marketing authorisation application to the EMA for its lead drug candidate MaaT013, under the registered brand name of Xervyteg.
